Respiratory tract infection – European Clinical Trials Information Network

A study to evaluate the effectiveness of a drug combination in reducing respiratory tract infections in children aged 3 to 12 years.

Wed, 29 Apr 2026 15:10:06 +0000

This study aims to evaluate the effectiveness of PMBL in reducing the occurrence of Respiratory Tract Infections, which are illnesses that affect the nose, throat, or lungs. The investigation involves comparing the use of Ismigen, a medication containing several bacteria such as Haemophilus influenzae, Klebsiella pneumoniae, Neisseria catarrhalis, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus viridans, and Klebsiella ozaenae, against a placebo. These medications will be administered as sublingual tablets, which are tablets that are placed under the tongue to dissolve.

During the course of the study, participants will be divided into groups to receive either the test medication or the placebo. The observation period includes a treatment phase during the fall and winter months, followed by a period to monitor health after the treatment has ended. The focus is on observing how often these infections occur and the duration of any illnesses experienced during this time.

A study testing the safety and effectiveness of inhaled hypochlorous acid in patients with chronic airway infections

Wed, 29 Apr 2026 15:08:23 +0000

This study is looking at chronic airway infections, which are long-lasting infections in the breathing passages. The study will test a treatment called SS0331, which contains hypochlorous acid as its active ingredient. This medication is given as a solution that is breathed in through a device called a nebuliser, which turns liquid medicine into a fine mist that can be inhaled into the lungs. The nebuliser system includes the Aerogen Solo nebuliser, Aerogen Ultra breathing chamber with mouthpiece, and Aerogen UBS controller.

The study has two parts. The first part will test the safety of SS0331 in healthy people by giving them increasing doses of the medicine three times a day for five days to see if it causes any unwanted effects. The purpose of the study is to see if SS0331 can reduce the amount of bacteria in the sputum, which is the mucus that people cough up from their lungs. The second part will test how well the treatment works in people who have chronic airway infections related to conditions such as cystic fibrosis, primary ciliary dyskinesia, or non-cystic fibrosis bronchiectasis. These are conditions where the airways are damaged or do not work properly, making it easier for infections to develop and persist.

During the study, participants will receive the nebulised SS0331 treatment three times daily for five days. The researchers will collect sputum samples to measure the number of bacteria present before and after treatment to see if the medication helps reduce the infection. They will also monitor participants for any side effects or unwanted reactions to the treatment. The study will help determine if this inhaled treatment is safe and whether it might be helpful for people living with chronic airway infections.

Study on Preventing Respiratory Infections in Elderly Patients Using OM85

Wed, 29 Apr 2026 14:59:18 +0000

This clinical trial is focused on preventing respiratory infections in elderly patients who have experienced at least two such infections in the past year. The study will use a medication called OM85, which is made from lyophilized bacterial lysates. This means it contains small parts of bacteria that are processed in a way to potentially help the body build a defense against infections. The trial will compare the effects of OM85 to a placebo to see if it can reduce the number of respiratory infections over a 12-month period.

The study will involve elderly patients living in healthcare residences. Participants will receive either OM85 or a placebo for six months, and their health will be monitored for an additional six months. The main goal is to see if OM85 can lower the number of respiratory infections. Additionally, the study will look at other factors such as hospital admissions, emergency room visits, and the use of antibiotics during the 12 months following the start of the treatment.

Throughout the study, researchers will also review medical records to check for any side effects of OM85 in elderly patients. This trial aims to provide valuable information on whether OM85 can be an effective way to prevent respiratory infections in older adults who are at risk.

Study on Nitric Oxide and Saline Nasal Sprays for Treating COVID-19 and Similar Illnesses in Primary Care Patients

Wed, 29 Apr 2026 14:30:24 +0000

This clinical trial is focused on studying the treatment of COVID-19 and illnesses that resemble COVID-19, often referred to as COVID-like illnesses. The treatment being tested is a Nitric Oxide Nasal Spray (NONS), which is a nasal spray containing nitric oxide, a chemical substance. The study will also use a Saline Nasal Spray (0.9% NaCl), which is a simple saltwater solution, as a comparison. The purpose of the study is to evaluate how effective the Nitric Oxide Nasal Spray is in helping people recover from symptoms of COVID-19 or similar illnesses.

Participants in the study will use the nasal sprays for a period of up to seven days. During this time, researchers will monitor how quickly participants feel better from their symptoms and how the treatment affects the virus in their bodies. The study will also look at how the treatment impacts the severity of the illness and the body’s immune response. Participants will be asked to report when they first feel recovered and how their symptoms change over time.

The study aims to gather information on how the treatment affects daily activities and overall well-being. It will also explore any long-term effects of COVID-19 or similar illnesses, such as fatigue or loss of taste and smell. The trial will help researchers understand the potential benefits of using Nitric Oxide Nasal Spray in treating COVID-19 and related illnesses, providing valuable insights into managing these conditions in the future.

Study on the Safety of Mercaptamine with Standard Therapy for Hospitalized COVID-19 Pneumonia Patients Not Requiring High Oxygen Flows

Wed, 29 Apr 2026 14:22:54 +0000

This clinical trial is focused on studying the effects of a medication called cysteamine in patients who have been hospitalized with COVID-19 pneumonia. COVID-19 is a respiratory illness caused by the coronavirus, which can lead to severe lung infections. The trial aims to evaluate the safety of cysteamine when used alongside standard treatments for COVID-19 pneumonia. Cysteamine is being tested to see if it can help improve the condition of patients who do not require high levels of oxygen support.

Participants in the study will receive cysteamine in the form of hard capsules, taken orally. The study will monitor patients over a period of time to observe any side effects and to assess how the medication interacts with the body. The trial will also track the number of days it takes for patients to recover and be discharged from the hospital. The goal is to determine if cysteamine can be a safe and effective addition to the current treatment options for COVID-19 pneumonia.

Throughout the study, various health indicators will be measured, such as blood markers and the presence of the virus in the body. The trial will also look at how cysteamine affects the expression of certain genes related to the immune response. By the end of the study, researchers hope to gather valuable information on the potential benefits of cysteamine for patients with COVID-19 pneumonia.